Equities analysts predict that Heron Therapeutics, Inc. (NASDAQ:HRTX) will report earnings of ($0.87) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Heron Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.82) and the lowest estimate coming in at ($0.90). Heron Therapeutics reported earnings per share of ($1.24) during the same quarter last year, which would suggest a positive year-over-year growth rate of 29.8%. The company is scheduled to report its next earnings results on Tuesday, November 14th.

According to Zacks, analysts expect that Heron Therapeutics will report full year earnings of ($3.50) per share for the current financial year, with EPS estimates ranging from ($3.57) to ($3.36). For the next year, analysts expect that the company will post earnings of ($2.40) per share, with EPS estimates ranging from ($3.52) to ($1.56). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $4.53 million.

HRTX has been the topic of several analyst reports. Cantor Fitzgerald reiterated a “buy” rating on shares of Heron Therapeutics in a report on Monday, September 25th. Zacks Investment Research upgraded Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Wednesday, July 12th. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Cowen and Company set a $40.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Aegis reiterated a “buy” rating and set a $33.00 price target on shares of Heron Therapeutics in a report on Tuesday, July 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $28.50.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/06/heron-therapeutics-inc-hrtx-expected-to-announce-earnings-of-0-87-per-share.html.

Heron Therapeutics (NASDAQ HRTX) traded down 1.042% during midday trading on Friday, reaching $16.625. 217,374 shares of the company were exchanged. The firm’s 50 day moving average price is $15.90 and its 200-day moving average price is $15.11. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $20.85. The stock’s market capitalization is $900.04 million.

Institutional investors and hedge funds have recently modified their holdings of the stock. Legal & General Group Plc raised its holdings in Heron Therapeutics by 13.9% in the 1st quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,098 shares during the period. Quantbot Technologies LP raised its holdings in Heron Therapeutics by 2,619.6% in the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 12,024 shares during the period. Old West Investment Management LLC purchased a new stake in Heron Therapeutics in the 1st quarter valued at about $206,000. HighTower Advisors LLC raised its holdings in Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 1,700 shares during the period. Finally, Tudor Investment Corp ET AL purchased a new stake in Heron Therapeutics in the 1st quarter valued at about $253,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.